JP2024539512A5 - - Google Patents

Info

Publication number
JP2024539512A5
JP2024539512A5 JP2024548515A JP2024548515A JP2024539512A5 JP 2024539512 A5 JP2024539512 A5 JP 2024539512A5 JP 2024548515 A JP2024548515 A JP 2024548515A JP 2024548515 A JP2024548515 A JP 2024548515A JP 2024539512 A5 JP2024539512 A5 JP 2024539512A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid vaccine
vaccine according
approximately
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539512A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/047107 external-priority patent/WO2023069498A1/en
Publication of JP2024539512A publication Critical patent/JP2024539512A/ja
Publication of JP2024539512A5 publication Critical patent/JP2024539512A5/ja
Pending legal-status Critical Current

Links

JP2024548515A 2021-10-22 2022-10-19 Ｍｒｎａワクチン組成物 Pending JP2024539512A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163270964P 2021-10-22 2021-10-22
US63/270,964 2021-10-22
US202163290889P 2021-12-17 2021-12-17
US63/290,889 2021-12-17
US202263320647P 2022-03-16 2022-03-16
US63/320,647 2022-03-16
PCT/US2022/047107 WO2023069498A1 (en) 2021-10-22 2022-10-19 Mrna vaccine composition

Publications (2)

Publication Number Publication Date
JP2024539512A JP2024539512A (ja) 2024-10-28
JP2024539512A5 true JP2024539512A5 (enExample) 2026-01-26

Family

ID=84358887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548515A Pending JP2024539512A (ja) 2021-10-22 2022-10-19 Ｍｒｎａワクチン組成物

Country Status (6)

Country Link
US (1) US20250295755A1 (enExample)
EP (1) EP4419081A1 (enExample)
JP (1) JP2024539512A (enExample)
KR (1) KR20240090727A (enExample)
CA (1) CA3235867A1 (enExample)
WO (1) WO2023069498A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215531A1 (en) 2022-05-06 2023-11-09 Senda Biosciences, Inc. Complex lipid nanoparticles encapsulating polypeptides and uses thereof
WO2024220712A2 (en) * 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
CN119497628A (zh) * 2023-06-20 2025-02-21 石药集团巨石生物制药有限公司 一种抵抗呼吸道合胞病毒的mRNA疫苗及其制备方法
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
WO2025106930A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
WO2025179198A1 (en) 2024-02-23 2025-08-28 Sail Biomedicines, Inc. Circular polyribonucleotides and unmodified linear rnas with reduced immunogenicity

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
ATE219660T1 (de) 1994-09-30 2002-07-15 Inex Pharmaceuticals Corp Mittel zum einbringen polyanionischer materialien in zellen
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
EP1903054A3 (de) 2001-06-05 2008-07-23 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
WO2005120152A2 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
WO2007086883A2 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2009003222A1 (en) 2007-06-29 2009-01-08 Commonwealth Scientific And Industrial Research Organisation Methods for degrading toxic compounds
EP3156414B1 (en) 2007-09-26 2019-12-04 Intrexon Corporation Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression
CN103911378A (zh) 2007-12-11 2014-07-09 斯克利普斯研究所 涉及mRNA翻译增强因子的组合物和方法
EP2379083B1 (en) 2008-12-18 2017-08-16 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
CA2764158A1 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
EP3165234B1 (de) 2009-07-31 2019-04-03 ethris GmbH Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
PT2717893T (pt) 2011-06-08 2019-08-20 Translate Bio Inc Composições de nanopartículas lipídicas e métodos para transferência de arnm
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20150000461A (ko) 2011-10-27 2015-01-02 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
CN108949772A (zh) 2012-04-02 2018-12-07 现代泰克斯公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
WO2013185069A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Pulmonary delivery of mrna to non-lung target cells
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
US20160022840A1 (en) 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
ES2882110T3 (es) 2013-03-14 2021-12-01 Translate Bio Inc Métodos y composiciones para administrar anticuerpos codificados con ARNm
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
EP2983804A4 (en) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ion exchange purification of mrna
EP4614148A3 (en) 2013-03-15 2025-12-17 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
WO2014144711A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
EP2971161B1 (en) 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification
AU2014310933B2 (en) 2013-08-21 2020-05-14 CureVac SE Method for increasing expression of RNA-encoded proteins
US9925277B2 (en) 2013-09-13 2018-03-27 Modernatx, Inc. Polynucleotide compositions containing amino acids
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
PT3083556T (pt) 2013-12-19 2020-03-05 Novartis Ag Lípidos e composições lipídicas para a entrega de agentes ativos
CN111304231A (zh) 2013-12-30 2020-06-19 库瑞瓦格股份公司 人工核酸分子
WO2015101415A1 (en) 2013-12-30 2015-07-09 Curevac Gmbh Artificial nucleic acid molecules
DK3134131T3 (en) 2014-04-23 2022-02-07 Modernatx Inc Nucleic acid vaccines
US10022455B2 (en) 2014-05-30 2018-07-17 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
WO2015196118A1 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015196130A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
IL316479A (en) 2014-06-25 2024-12-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
EP3169783A4 (en) 2014-07-17 2018-10-03 Modernatx, Inc. Terminal modifications of polynucleotides
WO2016118724A1 (en) 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016187531A1 (en) 2015-05-21 2016-11-24 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof
ES2949540T3 (es) 2015-06-19 2023-09-29 Massachusetts Inst Technology 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
RS63030B1 (sr) 2015-09-17 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
RS63986B1 (sr) 2015-10-28 2023-03-31 Acuitas Therapeutics Inc Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
EP3397613A1 (en) 2015-12-30 2018-11-07 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
SI3436077T1 (sl) 2016-03-30 2025-07-31 Intellia Therapeutics, Inc. Formulacije lipidnih nanodelcev za komponente crispr/cas
US10457631B2 (en) 2016-04-06 2019-10-29 Ohio State Innovation Foundation Biodegradable amino-ester nanomaterials for nucleic acid delivery
JP6983455B2 (ja) 2016-09-14 2021-12-17 モデルナティーエックス， インコーポレイテッド 高純度ｒｎａ組成物及びその調製のための方法
MX2019004913A (es) 2016-10-26 2019-09-16 Curevac Ag Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
WO2019027999A1 (en) 2017-07-31 2019-02-07 Ohio State Innovation Foundation BIOMIMETIC NANOMATERIALS AND USES THEREOF
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
CN111212905A (zh) 2017-08-18 2020-05-29 摩登纳特斯有限公司 Rna聚合酶变体
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
EP3709987B1 (en) 2017-11-14 2026-04-29 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derived ester lipids and uses thereof
SG11202101777VA (en) * 2018-08-24 2021-03-30 Flagship Pioneering Innovations Vi Llc Methods and compositions for the modification of plants
CN113039174B (zh) 2018-10-02 2023-11-17 英特利亚治疗股份有限公司 可电离的胺脂质
US12583816B2 (en) 2018-10-18 2026-03-24 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
KR20210108969A (ko) 2018-12-05 2021-09-03 인텔리아 테라퓨틱스, 인크. 변형된 아민 지질
JP7523449B2 (ja) 2019-01-11 2024-07-26 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
BR112021021313A2 (pt) 2019-04-25 2022-01-18 Intellia Therapeutics Inc Lipídios de amina ionizáveis e nanopartículas de lipídio
WO2021041301A1 (en) 2019-08-24 2021-03-04 Flagship Pioneering Innovations Vi, Llc Modification of plant messenger packs with charged lipids
JP2023511633A (ja) 2020-01-28 2023-03-20 モデルナティエックス インコーポレイテッド コロナウイルスｒｎａワクチン
TW202200199A (zh) 2020-03-20 2022-01-01 美商百歐恩泰美國公司 冠狀病毒疫苗及使用方法

Similar Documents

Publication Publication Date Title
JP7523897B2 (ja) 呼吸器合胞体ウイルス（ｒｓｖ）ワクチン
US20260091101A1 (en) Bunyavirales vaccine
US10358630B2 (en) Recombinant influenza vectors with tandem transcription units
TW202140518A (zh) 冠狀病毒疫苗
US7723094B2 (en) Recombinant influenza vectors with a polII promoter and ribozymes for vaccines and gene therapy
CN110478479B (zh) 用于活的减毒病毒的方法和组合物
WO2021159130A3 (en) Coronavirus rna vaccines and methods of use
JP2012021030A (ja) 新規組成物
TW202333780A (zh) 冠狀病毒疫苗
JP2016106093A (ja) インフルエンザワクチンの製造方法
ES2689150T3 (es) Métodos para la prevención de agregación de componentes víricos
JP2004501639A5 (enExample)
Kopecky-Bromberg et al. Recombinant vectors as influenza vaccines
JP2012510822A (ja) ウイルス増殖を誘導するための組成物、方法、および使用
MX2024005482A (es) Vacunas hibridas multivalentes antigripales que comprenden hemaglutinina y neuraminidasa y metodos de uso de las mismas.
TW202539697A (zh) 冠狀病毒疫苗
Mooney et al. Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses
Binjawadagi et al. Mucosal delivery of recombinant vesicular stomatitis virus vectors expressing envelope proteins of respiratory syncytial virus induces protective immunity in cotton rats
CA2380514A1 (en) Attenuated influenza virus useful as vaccine
Greer et al. Long‐term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus‐based replicon particles
JP2024543954A5 (enExample)
Elliott Bunyaviruses: general features
WO2025149907A1 (en) Influenza vaccines
WO2025052417A1 (en) Thermostable composition comprising vesiculo virus
WO2024174012A1 (pt) Composição imunogênica, uso da mesma e processo de obtenção de uma composição imunogênica combinada contra covid-19 e influenza sazonal